AVILAR THERAPEUTICS

At Avilar, we are moving beyond the boundaries of the cell to pioneer the discovery and development of extracellular protein degraders. Our ATACs (ASGPR Targeting Chimeras) are a new class of protein degrader therapeutics that shuttle disease-causing proteins from the circulation to the endolysosome where they are degraded... Protein degradation has emerged as a powerful new drug modality focused to date on intracellular targets. Avilar is now moving protein degradation beyond the interior of the cell to target extracellular and membrane bound proteins. With nearly 40% of human proteins located outside the cell and many having a clearly defined role in the pathogenesis of human diseases, we are developing novel degraders of extracellular proteins as future standard of care medicines for the treatment of multiple serious diseases... We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a natural endogenous process for protein degradation. We..

Also known as: Avilar, Avilar Therapeutics, Inc.

Primary location: Waltham United States